New hope for elderly kidney cancer patients: drug safety under review
NCT ID NCT04416646
First seen Apr 17, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment is a good option for older patients who have already tried other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Istituto Oncologico Veneto
Padova, Italy, 35100, Italy
Conditions
Explore the condition pages connected to this study.